(Gastrografin Use in Small Bowel Obstruction Caused by Adherences) - Full Text View

Purpose

Adhesive small intestine obstruction (ASIO) is an important cause of hospital admission and a very common disease. Any improvement in this field will benefit many patients by reducing the operative rate. Patients with this disease are difficult to evaluate and to manage and their treatment is controversial. Emergency surgery is mandatory when strangulation is suspected or in the case of total obstruction. On the other hand, conservative non-operative treatment is indicated in the case of partial obstruction. The role of water-soluble contrast medium (Gastrografin®: GG) in ASIO is still debated with regard to the therapeutic value.

The aim of our study was to determine the therapeutic role of Gastrografin in patients with small intestine obstruction without strangulation caused by adherences (ASIO).

Condition	Intervention	Phase
Adhesive Small Intestine Obstruction	Other: traditional conservative treatment (TT) Drug: Gastrografin®: G	Phase IV

MedlinePlus related topics:

Drinking Water

Drug Information available for:

Amidotrizoic Acid Diatrizoate Diatrizoate meglumine Diatrizoate Sodium

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study

Official Title:	Gastrografin Use in Small Bowel Obstruction Caused by Adherences

Further study details as provided by University of Bologna:

Primary Outcome Measures:

The operative rate in ASIO patients [ Time Frame: Within 72 hours and during hospital stay ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

The incidence of major and minor complications of treatments in the two arm [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
The ASIO recurrences [ Time Frame: 1 year ] [ Designated as safety issue: No ]
The time to resolution of obstruction [ Time Frame: Within hospital stay ] [ Designated as safety issue: No ]
The length of hospital stay [ Time Frame: Within hospital admission period ] [ Designated as safety issue: No ]

Enrollment:	76
Study Start Date:	September 2003
Study Completion Date:	November 2006

Arms	Assigned Interventions
GG: Experimental	Drug: Gastrografin®: G The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
TT	Other: traditional conservative treatment (TT) In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adult patients (>18 years)
History of previous abdominal surgical procedures
Clinical and radiological evidence of adhesive small intestine obstruction without signs of strangulation and peritonism
ASA I-III patients
Informed consent

Exclusion Criteria:

Suspicion of strangulation
Actual presence or high suspicion of intra-abdominal malignancy
Suspicion or history of peritoneal carcinomatosis
active inflammatory bowel disease
Positive history of radiotherapy on the abdominal region
Obstructed hernias

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00601809

Locations


Italy
	S.Orsola-Malpighi University Hospital - University of Bologna
	BOLOGNA, Italy
	Emergency Surgery Department - University of Modena
	Modena, Italy

Sponsors and Collaborators

University of Bologna

Investigators


Principal Investigator:	Fausto Catena, MD, PhD	S.Orsola-Malpighi University Hospital - University of Bologna

Principal Investigator:	Luca Ansaloni, MD	S.Orsola-Malpighi University Hospital - University of Bologna

Principal Investigator:	Margherita Gavioli, MD	University of Modena

Principal Investigator:	Salomone Di Saverio, M.D.	S.Orsola-Malpighi University Hospital - University of Bologna

More Information

Responsible Party:	S. Orsola Malpighi University Hospital - University of Bologna ( Dr. Fausto Catena M.D. PhD )
Study ID Numbers:	GUSBOCA
First Received:	January 14, 2008
Last Updated:	January 25, 2008
ClinicalTrials.gov Identifier:	NCT00601809
Health Authority:	Italy: Ethics Committee

Keywords provided by University of Bologna:

Gastrointestinal

Adhesive Small Intestine Obstruction

Oral water soluble contrast

Non-operative Conservative Management

Operative rate

Hospital stay

Study placed in the following topic categories:

Intestinal Obstruction

Digestive System Diseases

Gastrointestinal Diseases

Intestinal Diseases

ClinicalTrials.gov processed this record on October 28, 2008

Sponsored by:	University of Bologna
Information provided by:	University of Bologna
ClinicalTrials.gov Identifier:	NCT00601809